hEGFR Mouse
Product Name
hEGFR Mouse
Product ID
C001782
Strain Name
C57BL/6NCya-Egfrtm1(hEGFR)/Cya
Backgroud
C57BL/6NCya
Status
When using this mouse strain in a publication, please cite “hEGFR Mouse (Catalog C001782) were purchased from Cyagen.”
Product Type
Age
Genotype
Sex
Quantity
Gene Name
Egfr
Gene Alias
Wa5, wa2, Erbb, Errp, wa-2, Errb1, 9030024J15Rik
NCBI ID
Chromosome
Chr 11 (Mouse)
MGI ID
Datasheet
Strain Description
The Epidermal Growth Factor Receptor (EGFR) gene (also known as ERBB1 or HER1) encodes a transmembrane glycoprotein that belongs to the protein kinase superfamily. It is widely expressed in various cellular tissues, including epithelial and mesenchymal cells, bone cells, blood and immune cells, heart cells, glia, and stem neural cells, and is particularly abundant in the placenta [1]. Its primary function is to act as a receptor for members of the epidermal growth factor family, such as EGF and TGF-alpha. Upon ligand binding, EGFR undergoes dimerization and tyrosine autophosphorylation, initiating crucial downstream signaling pathways (like RAS-RAF-MEK-ERK and PI3 kinase-AKT) that regulate essential cellular processes including proliferation, survival, differentiation, and migration [2]. Aberrant gene expression, particularly overexpression, amplification, or activating mutations in EGFR, leads to its constitutive activation, promoting uncontrolled cell growth and survival [3]. This dysregulation is a significant factor in the development and progression of numerous cancers, most notably non-small cell lung cancer (especially adenocarcinoma), glioblastoma, colorectal carcinoma, and breast carcinoma, making EGFR a key target for personalized cancer therapies [4].
The hEGFR mouse is a humanized model constructed by replacing exon 2 and part of intron 2 of the mouse Egfr gene with the EGFR Chimeric cDNA-WPRE BGH pA cassette. The murine signal peptide and partial extracellular domain are preserved. hEGFR mice can be used for research into the pathogenesis of various cancers, including non-small cell lung cancer (adenocarcinoma), glioblastoma, colorectal cancer, and breast cancer, as well as for the screening, development, and safety assessment of EGFR-targeted therapies.
Reference
Sabbah DA, Hajjo R, Sweidan K. Review on Epidermal Growth Factor Receptor (EGFR) Structure, Signaling Pathways, Interactions, and Recent Updates of EGFR Inhibitors. Curr Top Med Chem. 2020;20(10):815-834.
Sha C, Lee PC. EGFR-Targeted Therapies: A Literature Review. J Clin Med. 2024 Oct 25;13(21):6391.
Abourehab MAS, Alqahtani AM, Youssif BGM, Gouda AM. Globally Approved EGFR Inhibitors: Insights into Their Syntheses, Target Kinases, Biological Activities, Receptor Interactions, and Metabolism. Molecules. 2021 Nov 4;26(21):6677.
Kang X, Li R, Li X, Xu X. EGFR mutations and abnormal trafficking in cancers. Mol Biol Rep. 2024 Aug 21;51(1):924.
Strain Strategy
The exon 2 plus partial intron 2 of mouse Egfr will be replaced with the EGFR Chimeric cDNA-WPRE BGH pA cassette. The murine signal peptide and partial extracellular domain will be preserved.
Figure 1. Gene editing strategy of hEGFR Mice.
*EGFR Chimeric cDNA: Human EGFR partial extracellular domain + Mouse Egfr transmembrane-cytoplasmic domain
Application Area
EGFR-targeted drug screening, development, and evaluation;
Research on the pathological mechanisms and therapeutic approaches of various cancers, including non-small cell lung cancer (adenocarcinoma), glioblastoma, colorectal cancer, and breast cancer.
Contact Us
Connect with our experts for your custom animal model needs. Please fill out the form below to start a conversation or request a quote.
Cyagen values your privacy. We’d like to keep you informed about our latest offerings and insights. Your preferences:
You may unsubscribe from these communications at any time. See our Privacy Policy for details on opting out and data protection.
By clicking the button below, you consent to allow Cyagen to store and process the personal information submitted in this form to provide you the content requested.
